secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2023-03-10T23:59:59+00:00
Accession:  0000950170-23-007286
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux Therapeutics posts 2022 net loss of $63.1M; cash at $327M; JANX007 update expected 2H 2023
--------------------------------------------------------------------------------

- Net loss of $63.1M for FY2022, vs $32.7M in FY2021; R&D expenses doubled to $53.4M.
- Cash and short-term investments $327.0M at Dec 31, 2022, down from $375.0M at Dec 31, 2021.
- FDA clearance for JANX008 (EGFR-TRACTr) IND; JANX009 IND submission on track 2023.
- Interim clinical update from JANX007 (PSMA-TRACTr) Phase 1 trial expected in H2 2023.
- Janux states SVB exposure is immaterial and will not impact short- or long-term objectives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017023007286/0000950170-23-007286-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017023007286/janx-20230310.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-007286

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer